TidalSense will showcase their ground-breaking N-Tidal™ technology — an innovative combination of a novel respiratory sensor and AI platform, that is being submitted for assessment under Class 2a EU MDR as a diagnostic device for Chronic Obstructive Pulmonary Disease (COPD).
COPD is the 3rd leading cause of death worldwide, causing 3.23 million deaths in 2019 1. Globally it is estimated that approximately 70% of COPD worldwide may be underdiagnosed 2.
Over half a billion people worldwide suffer from a chronic respiratory condition such as Chronic Obstructive Pulmonary Disease and asthma, with nearly 11 million of those within the Middle East and North Africa region in 2019 3; however current clinical standard diagnostic technology has poor accuracy, poor specificity and poor usability.
As part of ABHI UK Pavilion, TidalSense will demonstrate their new AI-driven innovative technologies including N-Tidal Diagnose, which is scheduled for UK and EU launch in 2024 for rapid, accurate diagnostic testing of COPD with relaxed breathing, in under 5 minutes 4,5.
Mark Gleeson, Chief Commercial Officer: “Arab Health 2024 is a great opportunity for TidalSense to expand our market presence and forge valuable partnerships. Showcasing our innovative N-Tidal™ technology, we aim to demonstrate its commercial viability and clinical potential for widespread adoption in the healthcare sector. Our focus is on establishing relationships that will facilitate the entry of N-Tidal™ into new markets, particularly for COPD and asthma diagnostics. We’re excited about the prospects this event offers for growth and collaboration across the region.”
TidalSense has combined the use of a newly designed, highly sensitive carbon dioxide sensor, with a diagnostic AI algorithms - the first time AI has been used in COPD diagnostics in this way - cutting appointment times for patients from 30 minutes down to under 5 and giving patients and clinicians an accurate and definitive outcome within that time.
The sensor is embedded inside a handheld, 4G-connected device (N-Tidal handset) that measures respired CO2 more quickly and accurately than ever before. Patients breathe normally (tidal breathing) into the handset for approximately 1 minute, data is automatically transferred and processed in real-time into respiratory biomarkers on N-Tidal’s cloud platform, and diagnostic outputs (which includes disease severity) will be made available in minutes on a web-based dashboard for clinicians. The algorithms have been trained to accurately discriminate COPD from other common cardiorespiratory conditions with PPV & NPV of over 90%.
While COPD is the first condition to be diagnosed by N-Tidal, the same sensor captures the breath physiology to enable other conditions to also be identified. Our ambition is to progress our technology to diagnosis at the earliest stages of disease, even before symptoms have emerged. Asthma and other cardiorespiratory conditions will all come ‘on-line’ as further AI algorithms are trained against additional clinical datasets giving clinicians a depth and breadth of data previously unseen in a 5-minute test.
This development represents a revolution in respiratory medicine. The innovative approach to delivering a diagnostic outcome, without the need for highly trained specialists to administer the test, enables N-Tidal to bring affordable, accurate, and rapid respiratory diagnostics to the full spectrum of healthcare settings.
The Arab Health Exhibition & Congress is taking place from 29 January – 1 February 2024 at the Dubai World Trade Centre. Throughout the exhibition, TidalSense will be located in the ABHI UK Pavilion – Stand H2.G55.
